The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Coding variants in TREM2 increase risk for Alzheimer's disease
Open accessAbstract
The triggering receptor expressed on myeloid 2 (TREM2) is an immune phagocytic receptor expressed on brain microglia known to trigger phagocytosis and regulate the inflammatory response. Homozygous mutations in TREM2 cause Nasu-Hakola disease, a rare recessive form of dementia. A heterozygous TREM2 variant, p.R47H, was recently shown to increase Alzheimer''s disease (AD) risk. We hypothesized that if TREM2 is truly an AD risk gene, there would be additional rare variants in TREM2 that substantially affect AD risk. To test this hypothesis, we performed pooled sequencing of TREM2 coding regions in 2082 AD cases and 1648 cognitively normal elderly controls of European American descent. We identified 16 non-synonymous variants, six of which were not identified in previous AD studies. Two variants, p.R47H [P = 9.17 × 10(-4), odds ratio (OR) = 2.63 (1.44-4.81)] and p.R62H [P = 2.36 × 10(-4), OR = 2.36 (1.47-3.80)] were significantly associated with disease risk in single-variant analyses. Gene-based tests demonstrate variants in TREM2 are genome-wide significantly associated with AD [PSKAT-O = 5.37 × 10(-7); OR = 2.55 (1.80-3.67)]. The association of TREM2 variants with AD is still highly significant after excluding p.R47H [PSKAT-O = 7.72 × 10(-5); OR = 2.47 (1.62-3.87)], indicating that additional TREM2 variants affect AD risk. Genotyping in available family members of probands suggested that p.R47H (P = 4.65 × 10(-2)) and p.R62H (P = 6.87 × 10(-3)) were more frequently seen in AD cases versus controls within these families. Gel electrophoresis analysis confirms that at least three TREM2 transcripts are expressed in human brains, including one encoding a soluble form of TREM2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous TREM2 mutations linked with AD have been identified, including R47H, R62H, N68K, D87N, T96K, and so on.191,193”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with these enrichment analyses, both rare and common variants have been identified in core microglial genes, such as TREM213,14.”
From Variant-to-function mapping of late-onset Alzheimer’s disease GWAS signals in human microglial cell models implicates RTFDC1 at the CASS4 locus (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Homozygous mutations are associated with Nasu–Hakola disease (NHD),189 or frontotemporal dementia,190 while the TREM2 variants associates with AD are heterozygous.191”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, TREM2 variants associate with an increased risk of AD [15, 25, 38–40].”
From Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“supporting a strong immunological role in AD93–95 including TREM27,96, CD33, and IL34.”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [96]
In the citing paper
“Several other TREM2 variants that affect the expression of TREM2 also increased the risk of AD, including R62H, T66M, H157Y, and D87N.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [166]
In the citing paper
“Since the identification of R47H, additional rare variants in TREM2 have been associated with AD risk [138–140]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [139]
In the citing paper
“The risk from this variant has a comparable effect size with the APOEε4 allele (around 3-fold increased AD risk; 4,19–22).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [20]
In the citing paper
“In addition to the R47H variant, further TREM2 variants have been revealed to be risk factors of AD or other CNS diseases, such as R62H (8,20), H157Y (25), Q33X, T66M and Y38C (26,27).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Rare-Variant Association Testing for Sequencing Data with the Sequence Kernel Association Test
Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M., & Lin, X. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.05.029 · Cited by 2,373
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Flagged first, then by citations
Research works printed but not linked: 6
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1569
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1568
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1565
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1565
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1568
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1567
Cited by
Sorted by citations
Items 101–200 of 315
TREM2 Variants and Neurodegenerative Diseases: A Systematic Review and Meta-Analysis
Zhou, S.-L., Tan, C., Hou, X., Cao, X., Tan, L., & Yu, J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181038 · Cited by 68
Ma, L., Allen, M., Sakae, N., Ertekin-Taner, N., Graff-Radford, N. R., Dickson, D. W., Younkin, S. G., & Sevlever, D. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0137-9 · Cited by 70
Desplats, P., Gutierrez, A. M., Antonelli, M. C., & Frasch, M. G. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.10.013 · Cited by 74
Belsare, K. D., Wu, H., Mondal, D., Bond, A., Castillo, E., Jin, J., Jo, H., Roush, A. E., Pilla, K. B., Sali, A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114486119 · Cited by 68
Microglia, Trem2, and Neurodegeneration
Shi, Q., Gutierrez, R. A., & Bhat, M. A. (2025) · The Neuroscientist · doi:10.1177/10738584241254118 · Cited by 69
“Subsequent studies confirmed an additional mutation R62H along with R47H as the highest frequency changes in familiar AD cases (Jin and others 2014).”
Patel, D., Mez, J., Vardarajan, B. N., Staley, L. A., Chung, J., Zhang, X., Farrell, J. J., Rynkiewicz, M. J., Cannon‐Albright, L., Teerlink, C. C., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.1350 · Cited by 66
Modulation of β-Amyloid Fibril Formation in Alzheimer’s Disease by Microglia and Infection
Brown, M. R., Radford, S. E., & Hewitt, E. W. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.609073 · Cited by 67
Lue, L.-F., Schmitz, C., & Walker, D. G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.050 · Cited by 63
Hall-Roberts, H., Agarwal, D., Obst, J., Smith, T. B., Monzón-Sandoval, J., Di Daniel, E., Webber, C., James, W. S., Mead, E., Davis, J. B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00709-z · Cited by 62
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
Self-citationRare TREM2 variants associated with Alzheimer’s disease display reduced cell surface expression
Sirkis, D. W., Bonham, L. W., Aparicio, R. E., Geier, E. G., Ramos, E. M., Wang, Q., Karydas, A., Miller, Z. A., Miller, B. L., Coppola, G., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0367-7 · Cited by 61
Novel targets in Alzheimer’s disease: A special focus on microglia
Balducci, C., & Forloni, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.017 · Cited by 62
Impact of aging immune system on neurodegeneration and potential immunotherapies
Liang, Z., Zhao, Y., Ruan, L., Zhu, L., Jin, K., Zhuge, Q., Su, D., & Zhao, Y. L. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.07.006 · Cited by 64
The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia
Tasaki, S., Gaiteri, C., Mostafavi, S., Jager, P. L. D., & Bennett, D. A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00699 · Cited by 61
Genetics of Alzheimer’s disease: From pathogenesis to clinical usage
Shao, W., Peng, D., & Wang, X. (2017) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2017.06.074 · Cited by 64
The Correlation between Inflammatory Biomarkers and Polygenic Risk Score in Alzheimer’s Disease
Morgan, A. R., Touchard, S., O’Hagan, C., Sims, R., Majounie, E., Escott‐Price, V., Jones, L., Williams, J. H., & Morgan, B. P. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160889 · Cited by 60
Assessment of the Genetic Architecture of Alzheimer’s Disease Risk in Rate of Memory Decline
Del-Aguila, J. L., Fernández, M. V., Schindler, S., Ibanez, L., Deming, Y., Ma, S., Saef, B., Black, K., Budde, J., Norton, J., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170834 · Cited by 60
Self-citationWang, L., Nykänen, N.-P., Western, D., Gorijala, P., Timsina, J., Li, F., Wang, Z., Ali, M., Yang, C., Liu, M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00687-4 · Cited by 58
Self-citationRole of TREM2 in Alzheimer’s Disease: A Long Road Ahead
Kulkarni, B., Kumar, D., Martins, N. A., & Sellamuthu, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02477-9 · Cited by 53
Biel, D., Suárez‐Calvet, M., Hager, P., Rubinski, A., Dewenter, A., Steward, A., Roemer, S. N., Ewers, M., Haass, C., Brendel, M., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202216987 · Cited by 56
More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk
Rosenthal, S. L., Bamne, M. N., Wang, X., Berman, S., Snitz, B. E., Klunk, W. E., Sweet, R. A., Demirci, F. Y., López, O. L., & Kamboh, M. I. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.04.012 · Cited by 54
Li, S., Hayden, E. Y., Garcia, V. J., Fuchs, D.-T. S., Sheyn, J., Daley, D. A., Rentsendorj, A., Torbati, T., Black, K. L., Rutishauser, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00049 · Cited by 48
Keogh, M. J., Wei, W., Wilson, I., Coxhead, J., Ryan, S., Rollinson, S. J., Griffin, H. R., Kurzawa‐Akanbi, M., Santibanez‐Koref, M., Talbot, K., et al. (2016) · Genome Research · doi:10.1101/gr.210609.116 · Cited by 51
Pocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
From Common to Rare Variants: The Genetic Component of Alzheimer Disease
Nicolas, G., Charbonnier, C., & Campion, D. (2016) · Human Heredity · doi:10.1159/000452256 · Cited by 50
Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L. M., Farias, F., Wilkins, C. H., Deming, Y. K., Henson, R. L., Mikesell, R. J., Piccio, L. M., et al. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000571 · Cited by 50
Self-citationCharacterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model
Wang, Y., Zhang, X., Song, Q., Hou, Y., Liu, J., Sun, Y., & Wang, P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00598-2 · Cited by 51
Plasma Markers of Inflammation Linked to Clinical Progression and Decline During Preclinical AD
Gross, A. L., Walker, K. A., Moghekar, A. R., Pettigrew, C., Soldan, A., Albert, M. S., & Walston, J. D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00229 · Cited by 49
The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer’s Disease
Yin, X., Qiu, Y., Zhao, C., Zhou, Z., Bao, J., & Qian, W. (2021) · Medical Science Monitor · doi:10.12659/msm.933084 · Cited by 48
Deming, Y. K., Li, Z., Benítez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 51
Self-citationCaspase-8, association with Alzheimer’s Disease and functional analysis of rare variants
Rehker, J., Rodhe, J., Nesbitt, R., Boyle, E. A., Martin, B., Lord, J., Karaca, I., Naj, A. C., Jessen, F., Helisalmi, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185777 · Cited by 51
Self-citationMechanistic insights into the deleterious roles of Nasu-Hakola disease associated TREM2 variants
Dash, R., Choi, H. J., & Moon, I. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-60561-x · Cited by 47
TREM2 splice isoforms generate soluble TREM2 species that disrupt long-term potentiation
Moutinho, M., Coronel, I., Tsai, A. P., Di Prisco, G. V., Pennington, T., Atwood, B. K., Puntambekar, S. S., Smith, D. C., Martinez, P., Han, S., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01160-z · Cited by 42
Alzheimer’s Disease: From Genetic Variants to the Distinct Pathological Mechanisms
Sun, Q., Xie, N., Tang, B., Li, R., & Shen, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00319 · Cited by 46
Singh, A. K., Mishra, G., Maurya, A., Awasthi, R., Kumari, K., Thakur, A., Rai, A., Rai, G. K., Sharma, B., Kulkarni, G. T., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190903102822 · Cited by 45
McMillan, I. O., Li, J., & Wang, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00247.2022 · Cited by 49
Dean, H. B., Roberson, E. D., & Song, Y. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01252 · Cited by 43
Alzheimer’s disease: rare variants with large effect sizes
Del-Aguila, J. L., Koboldt, D. C., Black, K., Chasse, R., Norton, J., Wilson, R. K., & Cruchaga, C. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.07.008 · Cited by 41
Self-citationRoles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 46
Abbas, K., Mustafa, M., Alam, M., Habib, S., Ahmad, W., Adnan, M., Hassan, M. I., & Usmani, N. (2025) · Neurogenetics · doi:10.1007/s10048-025-00821-y · Cited by 48
Takata, K., Ginhoux, F., & Shimohama, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114754 · Cited by 40
Gao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 48
Profiling TREM2 expression in amyotrophic lateral sclerosis
Jericó, I., Vicuña‐Urriza, J., Blanco‐Luquin, I., Macías, M., Martínez‐Merino, L., Roldán, M., Rojas‐García, R., Pagola, I., Carbayo, Á., de Luna, N., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.01.013 · Cited by 43
Greven, J. A., Wydra, J. R., Greer, R. A., Zhi, C., Price, D. A., Svoboda, J. D., Camitta, C. L. M., Washington, M., Leung, D. W., Song, Y., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00795-9 · Cited by 42
Li, R., Wang, X., & He, P. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9778 · Cited by 39
Zhang, D., Fan, Y., Wang, D., Bi, R., Zhang, C., Fang, Y., & Yao, Y. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9353-5 · Cited by 41
Inflammation as a Possible Link Between Dyslipidemia and Alzheimer’s Disease
Oliveira, B. C. D. L., Bellozi, P. M. Q., Reis, H. J., & de Oliveira, A. C. P. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.012 · Cited by 39
Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases
Baidya, F., Bohra, M., Datta, A., Sarmah, D., Shah, B., Jagtap, P., Raut, S., Sarkar, A., Singh, U., Kalia, K., et al. (2020) · Immunology · doi:10.1111/imm.13264 · Cited by 39
TREM2 variants and risk of Alzheimer’s disease: a meta-analysis
Lu, Y., Liu, W., & Wang, X. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2274-2 · Cited by 37
Obst, J., Hall-Roberts, H. L., Smith, T. B., Kreuzer, M., Magno, L., Di Daniel, E., Davis, J. B., & Mead, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-96144-7 · Cited by 36
López-López, A., Gelpí, E., Lopategui, D. M., & Vidal-Taboada, J. M. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0489-3 · Cited by 35
Microglia in Alzheimer's Disease: A Role for Ion Channels
Thei, L., Imm, J. L., Kaisis, E., Dallas, M. L., & Kerrigan, T. L. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00676 · Cited by 37
Meprin β cleaves TREM2 and controls its phagocytic activity on macrophages
Berner, D. K., Wessolowski, L., Armbrust, F., Schneppenheim, J., Schlepckow, K., Koudelka, T., Scharfenberg, F., Lucius, R., Tholey, A., Kleinberger, G., et al. (2020) · The FASEB Journal · doi:10.1096/fj.201902183r · Cited by 39
Fernández, M. V., Liu, M., Beric, A., Johnson, M., Cetin, A., Patel, M. R., Budde, J., Kohlfeld, P., Bergmann, K., Lowery, J., et al. (2024) · Scientific Data · doi:10.1038/s41597-024-03485-9 · Cited by 41
Self-citationOlive, C., Ibanez, L., Farias, F. H. G., Wang, F., Budde, J. P., Norton, J. B., Gentsch, J., Morris, J. C., Li, Z., Dube, U., et al. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-200019 · Cited by 32
Self-citationThe Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention
Merlo, S., Spampinato, S. F., Caruso, G. I., & Sortino, M. A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200131105418 · Cited by 35
CELF2 regulates the species-specific alternative splicing of TREM2
Yanaizu, M., Washizu, C., Nukina, N., Satoh, J., & Kino, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-75057-x · Cited by 32
Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease
Fernández, M. V., Kim, J. H., Budde, J., Black, K., Medvedeva, A., Saef, B. A., Deming, Y. K., Del‐Aguila, J. L., Ibáñez, L., Dube, U., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1007045 · Cited by 35
Self-citationSystematic review of genetic association studies in people with Lewy body dementia
Sanghvi, H., Singh, R., Morrin, H., & Rajkumar, A. P. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5260 · Cited by 34
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 33
Microglia in Alzheimer’s Disease: An Unprecedented Opportunity as Prospective Drug Target
Kulkarni, B., Martins, N. A., & Kumar, D. (2022) · Molecular Neurobiology · doi:10.1007/s12035-021-02661-x · Cited by 38
Identification of rare variants in Alzheimer’s disease
Lord, J., Lu, A. J., & Cruchaga, C. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00369 · Cited by 36
Self-citationVariant TREM2 Signaling in Alzheimer's Disease
Olufunmilayo, E. O., & Holsinger, R. M. D. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167470 · Cited by 33
Rare and low-frequency variants in human common diseases and other complex traits
Lettre, G. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102437 · Cited by 36
The X factor in neurodegeneration
Voskuhl, R. R., & Itoh, Y. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211488 · Cited by 35
TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 29
Caramello, A., Fancy, N. N., Tournerie, C., Eklund, M., Chau, V. M. N., Adair, E., Papageorgopoulou, M., Willumsen, N., Jackson, J., Hardy, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60328-w · Cited by 37
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 38
TREMs in Alzheimer's disease: Genetic and clinical investigations
Cheng, J. R., Guo, X., Zhang, T., Zhong, L., Bu, G., & Chen, X. (2016) · Clinica Chimica Acta · doi:10.1016/j.cca.2016.10.022 · Cited by 29
Microglia show differential transcriptomic response to Aβ peptide aggregates ex vivo and in vivo
McFarland, K. N., Ceballos, C., Rosario, A. M., Ladd, T. B., Moore, B. D., Golde, G., Wang, X., Allen, M., Ertekin‐Taner, N., Funk, C. C., et al. (2021) · Life Science Alliance · doi:10.26508/lsa.202101108 · Cited by 31
TREM2 risk variants are associated with atypical Alzheimer’s disease
Kim, B., Suh, E. R., Nguyen, A. T., Prokop, S., Mikytuck, B., Olatunji, O. A., Robinson, J. L., Grossman, M., Phillips, J. S., Irwin, D. J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02495-4 · Cited by 30
The Microglial Response to Neurodegenerative Disease
Song, W. M., & Colonna, M. (2018) · Advances in immunology · doi:10.1016/bs.ai.2018.04.002 · Cited by 30
Genome-Wide Association Studies for Cerebrospinal Fluid Soluble TREM2 in Alzheimer’s Disease
Liu, C., & Yu, J. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00297 · Cited by 27
Contribution of CNS and extra-CNS infections to neurodegeneration: a narrative review
Kettunen, P., Koıstınaho, J., & Rõlova, T. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03139-y · Cited by 30
Association of Variants in PINX1 and TREM2 With Late-Onset Alzheimer Disease
Tosto, G., Vardarajan, B. N., Sariya, S., Brickman, A. M., Andrews, H., Manly, J. J., Schupf, N., Reyes‐Dumeyer, D., Lantigua, R., Bennett, D. A., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1066 · Cited by 24
Kiianitsa, K., Kurtz, I., Beeman, N. E., Matsushita, M. M., Chien, W., Raskind, W. H., & Korvatska, O. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.2hi0720-463rr · Cited by 25
Lu, Y., Huang, X., Liang, W., Li, Y., Xing, M., Pan, W., Zhang, Y., Wang, Z., & Song, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104688 · Cited by 26
Del‐Aguila, J. L., Fernández, M. V., Jiménez, J. A., Black, K., Ma, S., Deming, Y. K., Carrell, D., Saef, B. A., Initiative, A. D. N., Howells, B., et al. (2015) · Alzheimer s Research & Therapy · doi:10.1186/s13195-015-0154-x · Cited by 25
Self-citationAltered heart rate variability during sleep in mild cognitive impairment
Kong, S. D., Hoyos, C. M., Phillips, C. L., McKinnon, A. C., Lin, P., Duffy, S. L., Mowszowski, L., LaMonica, H. M., Grunstein, R. R., Naismith, S. L., et al. (2020) · SLEEP · doi:10.1093/sleep/zsaa232 · Cited by 23
TREM2+ macrophages: a key role in disease development
Wang, X., Wang, Y., Yang, L. X., Zhang, Y., & Yang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550893 · Cited by 29
Xu, X., Du, L., Jiang, J., Yang, M., Wang, Z., Wang, Y., Tang, T., Fu, X., & Hao, J. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.716917 · Cited by 25
Key variants via the Alzheimer's Disease Sequencing Project whole genome sequence data
Wang, Y., Sarnowski, C., Lin, H., Pitsillides, A., Heard‐Costa, N. L., Choi, S. H., Wang, D., Bis, J. C., Blue, E., (ADNI), T. A. D. N. I., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13705 · Cited by 24
Kim, Y. W., Al‐Ramahi, I., Koire, A. M., Wilson, S. J., Konecki, D. M., Mota, S., Soleimani, S., Botas, J., & Lichtarge, O. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12240 · Cited by 22
Lin, C., Kong, Y., Chen, Q., Zeng, J., Pan, X., & Miao, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420731 · Cited by 24
TREM2 in Neurodegenerative Disorders: Mutation Spectrum, Pathophysiology, and Therapeutic Targeting
Yang, H.-W., Kim, D., Yang, Y., Bagyinszky, E., & An, S. S. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157057 · Cited by 26
TREM1: A Potential Therapeutic Target For Alzheimer’s Disease
Saadipour, K. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9716-y · Cited by 25
SORL1 variants across Alzheimer’s disease European American cohorts
NIA-LOAD family study group, N., Fernández, M. V., Black, K., Carrell, D., Saef, B. A., Budde, J., Deming, Y. K., Howells, B., Del‐Aguila, J. L., Ma, S., et al. (2016) · European Journal of Human Genetics · doi:10.1038/ejhg.2016.122 · Cited by 20
Self-citationStoiljković, M., Gutierrez, K. O., Kelley, C., Horváth, T. L., & Hajós, M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210041 · Cited by 21
Current understanding on TREM-2 molecular biology and physiopathological functions
Bharadwaj, S., Groza, Y., Mierzwicka, J. M., & Malý, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112042 · Cited by 23
Wang, P., Guo, Q., Zhou, Y. F., Chen, K., Xu, Y. F., Ding, D., Hong, Z., & Zhao, Q. (2017) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000188 · Cited by 21
Zhang, B., Li, R. Q., Zhang, Y., & Gao, X. (2020) · Medicine · doi:10.1097/md.0000000000018921 · Cited by 20
TREM2 in Neurodegenerative Diseases: Mechanisms and Therapeutic Potential
Li, L., Zheng, X., Ma, H., Zhu, M., Li, X., Sun, X., & Feng, X. (2025) · Cells · doi:10.3390/cells14171387 · Cited by 22
Tajmim, A., Cuevas-Ocampo, A. K., Siddique, A. B., Qusa, M. H., King, J. A., Abdelwahed, K. S., Sonju, J. J., & Sayed, K. A. E. (2021) · Nutrients · doi:10.3390/nu13051702 · Cited by 21
Ayyubova, G. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15914 · Cited by 21
TREM2 variants that cause early dementia and increase Alzheimer’s disease risk affect gene splicing
Kiianitsa, K., Lukes, M. E., Hayes, B. J., Brutman, J. N., Valdmanis, P. N., Bird, T. D., Raskind, W. H., & Korvatska, O. (2024) · Brain · doi:10.1093/brain/awae014 · Cited by 18
Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain
Szykowska, A., Chen, Y., Smith, T. B., Preger, C., Yang, J., Qian, D., Mukhopadhyay, S. M. M., Wigren, E., Neame, S. J., Gräslund, S., et al. (2021) · Structure · doi:10.1016/j.str.2021.06.010 · Cited by 20
Chen, Y., Chen, X., Guo, X., Song, W., Cao, B., Wei, Q., Ou, R., Zhao, B., & Shang, H. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2279-x · Cited by 18
Sánchez‐Ruiz de Gordoa, J., Erro, M. E., Vicuña‐Urriza, J., Zelaya, M. V., Tellechea, P., Acha, B., Zueco, S., Urdánoz‐Casado, A., Roldán, M., Blanco‐Luquin, I., et al. (2020) · Movement Disorders · doi:10.1002/mds.27992 · Cited by 18
Rosner, D., Sun, J., Cacace, R., Yee, A., Wagh, C., Rychkova, A., Dunlap, M., Gulbranson, D. R., Ibrahim, A., Wang, X., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.11.022 · Cited by 20
Metadata
- Authors
- Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., Bertelsen, S., Goate, A. M., & Cruchaga, C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Goate, Alison M.
- Cruchaga, Carlos
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-04
- Volume
- 23
- Issue
- 21
- Pages
- 5838-5846
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC4189899
- OpenAlex
- W2107590165
- Cited by
- 314
- References
- 46
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 28 · 2023: 18 · 2022: 23 · 2021: 31 · 2020: 30 · 2019: 28 · 2018: 30 · 2017: 27 · 2016: 23 · 2015: 18 · 2014: 4
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Alvin J. Siteman Cancer Center (CA91842, #P30 CA91842)
- Georgia Clinical and Translational Science Alliance (UL1TR000448)
- National Institutes of Health (NIH P50, UL1TR000448, 5p30ns069329-02, AG05681, AG 03991, CA91842, NS069329)
- National Institute on Aging (RF1AG044546, AG03991, K01AG046374, AG 05681, R01AG035083, U24 AG21886, P 50 AG05681, R01AG041797, R01AG044546, AG026276, P50AG005681, P01 AG0 3991, P01AG003991, AG035083, U24AG026395, U24AG056270, P01AG026276, U24AG021886)
- National Cancer Institute (P30 CA 91842, CA91842, P30CA091842)
- National Institute of Neurological Disorders and Stroke (P30-NS069329)
- National Center for Research Resources (P30 CA91842)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- TREM2, Alzheimer's disease, genetic risk variants, microglia, non-synonymous variants, Nasu-Hakola disease, soluble TREM2, gene-based association, European-American population
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Brain, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Molecular Sequence Data, Receptors, Immunologic, Risk, Genetic Variation, Case-Control Studies, Open Reading Frames, Sequence Alignment, Alternative Splicing, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
